– USA, CA – Esker Therapeutics, a Foresite Labs-incubated precision medicine company that is reimagining the discovery, development, and treatment of autoimmune disorders, today announced the appointment of Dr. Zhengbin (Bing) Yao, Ph.D., to its board of directors.
“We are also excited to welcome Bing to our board, whose experience in leading immunology programs from development to market at several prominent biopharma companies will be highly valuable to Esker,” said CEO, Dr. June Lee.
About Dr. Bing Yao
Dr. Yao is an accomplished executive and scientist with more than 25 years of experience in the biotechnology and pharmaceutical industries. He was chairman, CEO, and co-founder of Viela Bio until it was acquired by Horizon Therapeutics in March 2021. Formerly, he was SVP, R&D, and head of respiratory, inflammation, and autoimmunity at MedImmune. Dr. Yao was also SVP and head of the Immuno-Oncology Franchise at AstraZeneca. During his tenure at MedImmune and AstraZeneca, he played key leadership roles in the development and approval of multiple novel biologics for autoimmune, respiratory, and immuno-oncology indications. Before joining MedImmune, Dr. Yao led the project team leaders group for immunology, neurosciences, virology, and metabolism for Genentech, and before that, served as vice president of research and corporate officer for Tanox before it was acquired by Genentech. Earlier in his career, Dr. Yao held key roles at Aventis and Amgen.
He received his Ph.D. in microbiology and immunology from the University of Iowa, has authored more than 50 peer-reviewed publications, and holds over 20 patents and patent applications.
About Esker Therapeutics
Esker is a precision medicines company looking to eliminate the “all-comer” approach that is seen with today’s treatments for people with autoimmune diseases. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, to create medicines that change the lives of people with autoimmune disease.
For more information: https://www.eskertx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.